Inflammatory Animal Model for Parkinson's Disease: The Intranigral Injection of LPS Induced the Inflammatory Process along with the Selective Degeneration of Nigrostriatal Dopaminergic Neurons
DL‑3‑n‑butylphthalide reduces microglial activation in lipopolysaccharide‑induced Parkinson's disease model mice
The Synergy of Aging and LPS Exposure in a Mouse Model of Parkinson's Disease
Characterization of the lipopolysaccharide induced model of Parkinson's disease: Role of oxidative stress and neuroinflammation - ScienceDirect
PDF) Further characterisation of the LPS model of Parkinson's disease: A comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat. | Pádraig Mulcahy -
Lipopolysaccharide animal models of Parkinson's disease: Recent progress and relevance to clinical disease - ScienceDirect
Intranasal LPS-Mediated Parkinson's Model Challenges the Pathogenesis of Nasal Cavity and Environmental Toxins | PLOS ONE
PDF) Lipopolysaccharide Animal Models for Parkinson's Disease
IJMS | Free Full-Text | Tubeimoside I Protects Dopaminergic Neurons Against Inflammation-Mediated Damage in Lipopolysaccharide (LPS)-Evoked Model of Parkinson's Disease in Rats
Parkinson's disease: a systemic inflammatory disease accompanied by bacterial inflammagens | bioRxiv
Protective effects of DL‑3‑n‑butylphthalide in the lipopolysaccharide‑induced mouse model of Parkinson's disease
The Endotoxin-Induced Neuroinflammation Model of Parkinson's Disease
Mechanism of miR-132-3p Promoting Neuroinflammation and Dopaminergic Neurodegeneration in Parkinson's Disease | eNeuro
Urate inhibits microglia activation to protect neurons in an LPS-induced model of Parkinson's disease | Journal of Neuroinflammation | Full Text
Frontiers | Altered Gut Microbiome in Parkinson's Disease and the Influence of Lipopolysaccharide in a Human α-Synuclein Over-Expressing Mouse Model
Intranasal LPS-Mediated Parkinson's Model Challenges the Pathogenesis of Nasal Cavity and Environmental Toxins | PLOS ONE
Frontiers | Review: The Role of Intestinal Dysbiosis in Parkinson's Disease
Lipopolysaccharide animal models of Parkinson's disease: Recent progress and relevance to clinical disease - ScienceDirect
The Effects of Novel Formulations of Edaravone and Curcumin in the Mouse Intrastriatal Lipopolysaccharide Model of Parkinson's Disease
Neuroprotective Effect of Swertiamarin in a Rotenone Model of Parkinson's Disease: Role of Neuroinflammation and Alpha-Synuclein Accumulation | ACS Pharmacology & Translational Science
Pramipexole inhibits astrocytic NLRP3 inflammasome activation via Drd3-dependent autophagy in a mouse model of Parkinson's disease | Acta Pharmacologica Sinica
Urate inhibits microglia activation to protect neurons in an LPS-induced model of Parkinson's disease | Journal of Neuroinflammation | Full Text
Is Porphyromonas gingivalis involved in Parkinson's disease? | SpringerLink
IJMS | Free Full-Text | Licochalcone A Prevents the Loss of Dopaminergic Neurons by Inhibiting Microglial Activation in Lipopolysaccharide (LPS)-Induced Parkinson's Disease Models
The Synergy of Aging and LPS Exposure in a Mouse Model of Parkinson's Disease
Frontiers | Genetic Imaging of Neuroinflammation in Parkinson's Disease: Recent Advancements
